ISKJ Stock Overview
Public Joint-Stock Company ‘Human Stem Cells Institute’ operates as a biotech company primarily in Russia.
Price History & Performance
|Historical stock prices|
|Current Share Price||₽104.15|
|52 Week High||₽177.00|
|52 Week Low||₽33.35|
|1 Month Change||-15.29%|
|3 Month Change||21.44%|
|1 Year Change||160.38%|
|3 Year Change||1,101.27%|
|5 Year Change||491.76%|
|Change since IPO||610.49%|
Recent News & Updates
Risks To Shareholder Returns Are Elevated At These Prices For Public Joint-Stock Company "Human Stem Cells Institute" (MCX:ISKJ)
When close to half the companies in Russia have price-to-earnings ratios (or "P/E's") below 10x, you may consider...
|ISKJ||RU Biotechs||RU Market|
Return vs Industry: ISKJ exceeded the Russian Biotechs industry which returned -19.3% over the past year.
Return vs Market: ISKJ exceeded the Russian Market which returned 6.1% over the past year.
|ISKJ Average Weekly Movement||15.5%|
|Biotechs Industry Average Movement||7.5%|
|Market Average Movement||4.9%|
|10% most volatile stocks in RU Market||8.9%|
|10% least volatile stocks in RU Market||3.1%|
Stable Share Price: ISKJ is more volatile than 90% of Russian stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: ISKJ's weekly volatility has increased from 10% to 16% over the past year.
About the Company
Public Joint-Stock Company ‘Human Stem Cells Institute’ operates as a biotech company primarily in Russia. The company engages in the drug discovery, research and development, and marketing of proprietary products and services in the field of regenerative medicine; bio-insurance; medical genetics, including reproductive genetics; gene therapy; and biopharmaceutics. It owns and operates Gemabank, a family cord blood stem cell bank in Russia and the CIS; and Reprobank, a reproductive cell and tissue bank for personal storage of reproductive cells and tissues, as well as a sperm/oocyte donation.
Human Stem Cells Institute Fundamentals Summary
|ISKJ fundamental statistics|
Is ISKJ overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ISKJ income statement (TTM)|
|Cost of Revenue||₽545.65m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.28|
|Net Profit Margin||1.69%|
How did ISKJ perform over the long term?See historical performance and comparison
Is Human Stem Cells Institute undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ISKJ (RUB104.15) is trading below our estimate of fair value (RUB177.12)
Significantly Below Fair Value: ISKJ is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ISKJ is poor value based on its PE Ratio (372.5x) compared to the European Biotechs industry average (27.9x).
PE vs Market: ISKJ is poor value based on its PE Ratio (372.5x) compared to the Russian market (7.7x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ISKJ's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ISKJ is overvalued based on its PB Ratio (33.6x) compared to the XE Biotechs industry average (3.9x).
How is Human Stem Cells Institute forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Human Stem Cells Institute has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Human Stem Cells Institute performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ISKJ has a large one-off loss of RUB23.8M impacting its June 30 2021 financial results.
Growing Profit Margin: ISKJ's current net profit margins (1.7%) are lower than last year (11.7%).
Past Earnings Growth Analysis
Earnings Trend: ISKJ has become profitable over the past 5 years, growing earnings by 64.9% per year.
Accelerating Growth: ISKJ's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: ISKJ had negative earnings growth (-80.9%) over the past year, making it difficult to compare to the Biotechs industry average (50.7%).
Return on Equity
High ROE: ISKJ's Return on Equity (8.2%) is considered low.
How is Human Stem Cells Institute's financial position?
Financial Position Analysis
Short Term Liabilities: ISKJ's short term assets (RUB531.0M) exceed its short term liabilities (RUB403.0M).
Long Term Liabilities: ISKJ's short term assets (RUB531.0M) do not cover its long term liabilities (RUB646.0M).
Debt to Equity History and Analysis
Debt Level: ISKJ's net debt to equity ratio (66.3%) is considered high.
Reducing Debt: ISKJ's debt to equity ratio has increased from 26% to 77.2% over the past 5 years.
Debt Coverage: ISKJ's debt is well covered by operating cash flow (50.9%).
Interest Coverage: ISKJ's interest payments on its debt are not well covered by EBIT (3x coverage).
What is Human Stem Cells Institute current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ISKJ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ISKJ's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ISKJ's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ISKJ's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: ISKJ is not paying a notable dividend for the Russian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ISKJ's dividend in 3 years as they are not forecast to pay a notable one for the Russian market.
How experienced are the management team and are they aligned to shareholders interests?
Prikhodko Viktorovich (62 yo)
Mr. Prikhodko Alexander Viktorovich, Ph D., served as Chairman of the Board of Public Joint-Stock Company "Human Stem Cells Institute" since July 30, 2012 until October 2020 and serves as its General Direc...
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Public Joint-Stock Company "Human Stem Cells Institute"'s employee growth, exchange listings and data sources
- Name: Public Joint-Stock Company "Human Stem Cells Institute"
- Ticker: ISKJ
- Exchange: MISX
- Founded: 2003
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ₽7.498b
- Shares outstanding: 71.99m
- Website: https://hsci.ru
- Public Joint-Stock Company "Human Stem Cells Institute"
- 18/1 Olimpiysky prospect
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/19 21:18|
|End of Day Share Price||2022/01/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.